

AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.

In the Claims:

Please cancel claims 7, 17, 26, 29-32 and 34-35 without prejudice or disclaimer.

Please amend claims 1, 10, 20 and 33 as follows.

B¹
1. (Amended) A method for preventing a symptom of herpes simplex virus infection in an individual who has been exposed to herpes simplex virus, comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5'-C, G-3', wherein the polynucleotide comprises a phosphate backbone modification, wherein a herpes simplex virus antigen is not administered in conjunction with administration of said composition, wherein the individual is a mammal and wherein said composition is administered in an amount sufficient to prevent a symptom of herpes simplex virus infection.

B²
10. (Amended) A method of reducing severity of a symptom of herpes simplex virus infection in an individual infected with herpes simplex virus, comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5'-C, G-3', wherein the polynucleotide comprises a phosphate backbone modification, wherein a herpes simplex virus antigen is not administered in conjunction with administration of said composition, wherein the individual is a mammal and wherein said composition is administered in an amount sufficient to reduce severity of a symptom of herpes simplex virus infection.

B³
20. (Amended) A method of reducing recurrence of a symptom of herpes simplex virus infection in an individual infected with herpes simplex virus, comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to

32 said individual, wherein the ISS comprises the sequence 5'-C, G-3', wherein the polynucleotide comprises a phosphate backbone modification, wherein a herpes simplex virus antigen is not administered in conjunction with administration of said composition, wherein the individual is a mammal and wherein said composition is administered in an amount sufficient to reduce recurrence of a symptom of herpes simplex virus infection.

33. (Amended) A kit for use in ameliorating or preventing a symptom of herpes simplex virus infection in an individual infected with, exposed to or at risk of being exposed to herpes simplex virus, comprising:

34 a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTTCGAGATGA-3' (SEQ ID NO:1) or the sequence 5'-TCGTCGAACGTTTCGTTAACGTTTCG-3' (SEQ ID NO:9), wherein the polynucleotide comprises a phosphate backbone modification and wherein said kit does not comprise a herpes simplex virus antigen; and

instructions for administration of said composition to an individual infected with, exposed to or at risk of being exposed to herpes simplex virus, wherein the individual is a mammal.